PMHNP ANCC Exam Questions And
Answers
Descriptive nVividness n- nAnswer n- nThe nresearcher ndescribes nthe ndata ngathering nprocess nin
nsufficient ndetail nthat nthe nreader ncan npersonally nexperience nit. nThe ndata ncollected, noften nin nthe
nform nof npersonal nstatements, nshould nbe nquoted ndirectly nand nextensively, nbecause nthis nis nthe
nraw ndata nfrom nthe nstudy.
Methodological nCongruence n- nAnswer n- nThe nresearcher npresents nthe nphilosophical nand
nmethodological napproach nused nand ncites nreferences nto nsupport ntheir napproach. nThe nsubjects,
nsampling nmethod, ndata-gathering nand ndata-analysis nstrategies, nand nprocesses nfor ninformed
nconsent nare nclearly nand nconcisely ndescribed.
Theoretical nConectedness n- nAnswer n- nAny ntheory ndeveloped nfrom nthe nstudy nis nclearly nstated,
nlogically nconsistent, nreflective nof nthe ndata, nand nin naccord nwith nother navailable nknowledge.
Analytical nPrecision n- nAnswer n- nIs nnot nconcerned nwith nstatistics nand ninstruments. nIf nrefers nto
nthe ndecision-making nprocess nby nwhich nthe nresearchers nsynthesize nconcrete ndata n(words nof nthe
nsubjects) ninto nan nabstract nthat nclarifies nthe nmeaning nand nthe nimportance nof nthe nstudy. nThe
nlast nof nthe n5 ncriteria nis nHeuristic nRelevance n- nThe nresearcher nclarifies nthe nsignificance nof nthe
nstudy, nits napplicability nto npublic nhealth nor ncommunity nnursing, nand nits nlikely ninfluence no nthe
nfuture nresearch.
Phenelzine n- nAnswer n- nAn nMAOI nthat npatients nwith natypical ndepression nrespond nparticularly
nwell nto.
Atomoxetine n- nAnswer n- nA nnorepinephrine nreuptake ninhibitor napproved nfor nthe ntreatment nof
nADHD.
Loxapine n- nAnswer n- nA ntypical, ntetracyclic nantipsychotic nwith nantidepressant nproperties. nIts
nactive nmetabolite nis namoxapine, nwhich nis na nsecondary namine ntricyclic nantidepressant.
,HITECH n- nAnswer n- nImplementation nof nEHR nfor ninformation nexchanges nand nimproving
npopulation nhealth. nThis nwas ndone nby nObama nand nthe nARRA.
Suppression n- nAnswer n- nThe nintentional nor nconscious nexclusion nof npainful nor ndisturbing
nthoughts nor nemotions nfrom nawareness. n
A nhealthy ndefense nmechanism nbecause nthe nclient nchannels nconflicting nenergies ninto ngrowth-
promoting nactivities.
Medications nthat ncan ninduce ndepression n- nAnswer n- nbeta nblockers, nsteroids, ninterferon,
nAccutane, nbenzodiazepines, nprogesterone, nsome nantivirals, nand nantineoplasmics.
Medications nthat ncan ninduce nmania n- nAnswer n- nSteroids, nIsoniazid, nantidepressants n(in npeople
nwho nalready nhave nbipolar ndisorder), nand nAntabuse.
Medigap nInsurance nPolicies n- nAnswer n- nPrivate ninsurance npolicies npurchased nby nelderly
nindividuals nto ncover nsome nor nall nof ntheir nmedical nexpenses nnot npaid nfor nby nMedicare.
Medicare nAdvantage nPlan n- nAnswer n- nFormerly nMedicare n+ nChoice, nthis ncreated nregional
nPreferred nProvider nOrganizations n(PPOs) nand ngave nMedicare nenrollees nthe noption nof nenrolling
nin nprivate ninsurance nplans.
Medicare n+ nChoice n- nAnswer n- nWas na npart nof nthe nBalanced nBudget nAct nof n1997 nthat
nsignificantly nincrease nthe nnumber nof nmanaged ncare ninsurance nplans navailable nto nrecipients. nThis
nwas nreplaced nwith nthe nMedicare nAdvantage nPlan nin n200.
List nof nthe nSecond nGeneration n(atypical) nAntipsychotics n(9) n- nAnswer n- nClozaril n(clozapine),
nZyprexa n(olanzapine), nLatuda n(lurasidone), nziprasidone, nRisperdal n(risperidone), nInvega nSustenna
n(palperidone), nFanapt n(iloperidone), nSeroquel n(quetiapine), nSaphris n(asenapine),
List nof nFirst nGeneration n(typical) nAntipsychotics n(10) n- nAnswer n- nHaldol n(haloperidol), nProlixin
n(fluphenazine), nNavane n(thiothixene), nThorazine n(chlorpromazine), nLoxitane n(loxapine), nMellaril
n(thioridazine), nTrilafon n(perphenazine), nOrap n(pimozide), nSolian namisulpride), nStellazine
n(trifluoperazine)
, List nthe n6 ncommon nbenzodiazepines nin norder nfrom nshortest nto nlongest nhalf-life n- nAnswer n-
nXanax n(alprazolam): n6-10 nhrs
Serax n(oxazepam): n8 nhrs
Ativan n(lorazepam): n12-18 nhrs
Klonopin n(clonazepam): n30-40 nhrs
Valium n(diazepam): n100 nhrs
Librium n(chlordiazepoxide): n36-200 nhrs
List nof nSNRIs n(6) n- nAnswer n- nCymbalta n(duloxetine), nPristiq n(desvenlafaxine), nEffexor
n(venlafaxine), nFetzima n(levomilnacipran), nSavella n(milnacipran), nStrattera n(atomoxetine)
Action nof nTricyclic nAntidepressants n(TCAs) n- nAnswer n- nThey ntarget nserotonin, nnorepinephrine,
nand nhistamine-1 nreceptors
List nthe nTricyclic nAntidepressants n(9) n- nAnswer n- nPamelor n(nortriptyline), nElavil n(amitriptyline),
namoxapine n(no nbranded), nAnafranil n(clomipramine), nNorpramin n(desipramine), nTofranil
n(imipramine), nVivactil n(protriptyline), nSinequan/Silenor n(doxepin), nSurmontil n(trimipramine)
FINISH nacronym nfor nSSRI nwithdrawal n- nAnswer n- nFlu-like nsymptoms
Irritability
Nausea
Imbalance/instability/incoordination/dizzy n(motor)
Sensory ndisturbances
Headache, nhyperarousal n(anxiety/agitation)
Signs nof nNMS n(Neuroleptic nMalignant nSyndrome) n- nAnswer n- nInitial nSymptoms: naltered
nsensorium, nhyperreflexia, nfever
Then nsigns nof nautonomic ninstability: nextreme nmuscle nrigidity, nhypotension, ntachycardia,
ndiaphoresis, ntachypnea, nhyperthermia, ncoma, ndeath. n
Check nfor nincreased nWBCs n(leukocytosis)/LFTs/CPK
Answers
Descriptive nVividness n- nAnswer n- nThe nresearcher ndescribes nthe ndata ngathering nprocess nin
nsufficient ndetail nthat nthe nreader ncan npersonally nexperience nit. nThe ndata ncollected, noften nin nthe
nform nof npersonal nstatements, nshould nbe nquoted ndirectly nand nextensively, nbecause nthis nis nthe
nraw ndata nfrom nthe nstudy.
Methodological nCongruence n- nAnswer n- nThe nresearcher npresents nthe nphilosophical nand
nmethodological napproach nused nand ncites nreferences nto nsupport ntheir napproach. nThe nsubjects,
nsampling nmethod, ndata-gathering nand ndata-analysis nstrategies, nand nprocesses nfor ninformed
nconsent nare nclearly nand nconcisely ndescribed.
Theoretical nConectedness n- nAnswer n- nAny ntheory ndeveloped nfrom nthe nstudy nis nclearly nstated,
nlogically nconsistent, nreflective nof nthe ndata, nand nin naccord nwith nother navailable nknowledge.
Analytical nPrecision n- nAnswer n- nIs nnot nconcerned nwith nstatistics nand ninstruments. nIf nrefers nto
nthe ndecision-making nprocess nby nwhich nthe nresearchers nsynthesize nconcrete ndata n(words nof nthe
nsubjects) ninto nan nabstract nthat nclarifies nthe nmeaning nand nthe nimportance nof nthe nstudy. nThe
nlast nof nthe n5 ncriteria nis nHeuristic nRelevance n- nThe nresearcher nclarifies nthe nsignificance nof nthe
nstudy, nits napplicability nto npublic nhealth nor ncommunity nnursing, nand nits nlikely ninfluence no nthe
nfuture nresearch.
Phenelzine n- nAnswer n- nAn nMAOI nthat npatients nwith natypical ndepression nrespond nparticularly
nwell nto.
Atomoxetine n- nAnswer n- nA nnorepinephrine nreuptake ninhibitor napproved nfor nthe ntreatment nof
nADHD.
Loxapine n- nAnswer n- nA ntypical, ntetracyclic nantipsychotic nwith nantidepressant nproperties. nIts
nactive nmetabolite nis namoxapine, nwhich nis na nsecondary namine ntricyclic nantidepressant.
,HITECH n- nAnswer n- nImplementation nof nEHR nfor ninformation nexchanges nand nimproving
npopulation nhealth. nThis nwas ndone nby nObama nand nthe nARRA.
Suppression n- nAnswer n- nThe nintentional nor nconscious nexclusion nof npainful nor ndisturbing
nthoughts nor nemotions nfrom nawareness. n
A nhealthy ndefense nmechanism nbecause nthe nclient nchannels nconflicting nenergies ninto ngrowth-
promoting nactivities.
Medications nthat ncan ninduce ndepression n- nAnswer n- nbeta nblockers, nsteroids, ninterferon,
nAccutane, nbenzodiazepines, nprogesterone, nsome nantivirals, nand nantineoplasmics.
Medications nthat ncan ninduce nmania n- nAnswer n- nSteroids, nIsoniazid, nantidepressants n(in npeople
nwho nalready nhave nbipolar ndisorder), nand nAntabuse.
Medigap nInsurance nPolicies n- nAnswer n- nPrivate ninsurance npolicies npurchased nby nelderly
nindividuals nto ncover nsome nor nall nof ntheir nmedical nexpenses nnot npaid nfor nby nMedicare.
Medicare nAdvantage nPlan n- nAnswer n- nFormerly nMedicare n+ nChoice, nthis ncreated nregional
nPreferred nProvider nOrganizations n(PPOs) nand ngave nMedicare nenrollees nthe noption nof nenrolling
nin nprivate ninsurance nplans.
Medicare n+ nChoice n- nAnswer n- nWas na npart nof nthe nBalanced nBudget nAct nof n1997 nthat
nsignificantly nincrease nthe nnumber nof nmanaged ncare ninsurance nplans navailable nto nrecipients. nThis
nwas nreplaced nwith nthe nMedicare nAdvantage nPlan nin n200.
List nof nthe nSecond nGeneration n(atypical) nAntipsychotics n(9) n- nAnswer n- nClozaril n(clozapine),
nZyprexa n(olanzapine), nLatuda n(lurasidone), nziprasidone, nRisperdal n(risperidone), nInvega nSustenna
n(palperidone), nFanapt n(iloperidone), nSeroquel n(quetiapine), nSaphris n(asenapine),
List nof nFirst nGeneration n(typical) nAntipsychotics n(10) n- nAnswer n- nHaldol n(haloperidol), nProlixin
n(fluphenazine), nNavane n(thiothixene), nThorazine n(chlorpromazine), nLoxitane n(loxapine), nMellaril
n(thioridazine), nTrilafon n(perphenazine), nOrap n(pimozide), nSolian namisulpride), nStellazine
n(trifluoperazine)
, List nthe n6 ncommon nbenzodiazepines nin norder nfrom nshortest nto nlongest nhalf-life n- nAnswer n-
nXanax n(alprazolam): n6-10 nhrs
Serax n(oxazepam): n8 nhrs
Ativan n(lorazepam): n12-18 nhrs
Klonopin n(clonazepam): n30-40 nhrs
Valium n(diazepam): n100 nhrs
Librium n(chlordiazepoxide): n36-200 nhrs
List nof nSNRIs n(6) n- nAnswer n- nCymbalta n(duloxetine), nPristiq n(desvenlafaxine), nEffexor
n(venlafaxine), nFetzima n(levomilnacipran), nSavella n(milnacipran), nStrattera n(atomoxetine)
Action nof nTricyclic nAntidepressants n(TCAs) n- nAnswer n- nThey ntarget nserotonin, nnorepinephrine,
nand nhistamine-1 nreceptors
List nthe nTricyclic nAntidepressants n(9) n- nAnswer n- nPamelor n(nortriptyline), nElavil n(amitriptyline),
namoxapine n(no nbranded), nAnafranil n(clomipramine), nNorpramin n(desipramine), nTofranil
n(imipramine), nVivactil n(protriptyline), nSinequan/Silenor n(doxepin), nSurmontil n(trimipramine)
FINISH nacronym nfor nSSRI nwithdrawal n- nAnswer n- nFlu-like nsymptoms
Irritability
Nausea
Imbalance/instability/incoordination/dizzy n(motor)
Sensory ndisturbances
Headache, nhyperarousal n(anxiety/agitation)
Signs nof nNMS n(Neuroleptic nMalignant nSyndrome) n- nAnswer n- nInitial nSymptoms: naltered
nsensorium, nhyperreflexia, nfever
Then nsigns nof nautonomic ninstability: nextreme nmuscle nrigidity, nhypotension, ntachycardia,
ndiaphoresis, ntachypnea, nhyperthermia, ncoma, ndeath. n
Check nfor nincreased nWBCs n(leukocytosis)/LFTs/CPK
